Syra Health Corp (SYRA) Form 8-K — Nov 3, 2026
Syra Health reported its third consecutive profitable quarter with record revenue of $2.6 million in Q3 2026, up 52% year-over-year from $1.7 million. Net income swung to $344,610 from a $(225,902) loss a year ago, with EPS of $0.02 versus $(0.02), and gross margin hit a company-record 46.3%, up 1,340 basis points. Nine-month net income reached $835,831 versus a $(761,763) loss last year, operating cash flow was $975,023, and the company ended the quarter with $2.4 million in cash and no long-term debt.
Key figures
- Eps
- 0.02
- Revenue
- 2557295
- Guidance
- Company remains on track for full-year profitability in 2026; expects quarter-to-quarter variability from RFP- and contract-driven timing.
- Net Income
- 344610
- Revenue Yoy
- 52%
- Total Assets
- 4225390
- Cash Position
- 2383413
- Gross margin
- 46.3%
- Ebitda q3 2026
- 301725
- Long term debt
- none
- Net income 9m 2026
- 835831
- Operating cash flow 9m
- 975023
- Gross margin prior year
- 32.9%
- Total debt notes payable
- 179272
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.